IV. Literaturverzeichnis
1. Mendonca LLF, Khamashta MA, Nelson-Piercy C, Hughes GRV. Non-steroidal anti-inflammatory drugs as a possible cause for reversible infertility. Rheumatology 2000; 39: 880-882.
2. Hickok DE, Hollenbach KA, Reilley SF, Nyberg DA. The association between decreased amniotic fluid volume and treatment with nonsteroidal anti-inflammatory agents for preterm labor. Am J Obstet Gynecol 1989;160:1525-1531.
3. Vermillion ST, Scardo JA, Lashus AG, Wiles HB. The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am J Obstet Gynecol 1997; 177: 256-261
4. Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology 1997;56:335-340;
5. Park-Wyllie L, Mazzotta P, Pastuszak A et al. Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000;62:385-92
6. Committee on Drugs. American Academy of pediatrics (2001). The Transfer of Drugs and Other Chemicals Into Human Milk. Pediatrics;108:776-789
7. Østensen M. Antirheumatische Therapie und Reproduktion. Z Rheumatol 2006; 65: 217-224
8. Wolfe MS, Cordero JF (1985) Safety of chloroquine in chemosuppression of malaria during pregnancy. BMJ 290: 1466-1467.
9. Fraga A, Mintz G, Orozco J et al (1974) Sterility and fertility rates, fetal wastage and maternal morbidity in systemic lupus erythematosus. J Rheumatol 1: 293 – 298.
10. Costedoat-Chalumeau N, Amoura Z, Duhaut P et al. (2004) Safety of Hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 50: 3057-3058.
11. Motta M, Tincani A, Faden D et al (2005) Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol 25: 86-89.
12. Costedoat-Chalumeau N, Amoura Z, Huong du LT et al. (2005) Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun Rev 4: 111-115.
13. Janssen NM, Genta MS (2000) The effects of immunosuppressive and anti.inflammatory medications on fertility, pregnancy and lactation. Arch Int Med 160: 610-619.
14. Temprano KK, Bandlamudi R, Moore TL (2005) Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum 35: 112-121.
15. O´Morain C, Smethurst P, Dore CJ et al (1984) Reversible male infertility due to sulphasalazine: studies in men and rat. Gut 25: 1078-1084.
16. Ferrero S, Ragni N (2004) Inflammatory Bowel Disease: Management issues during pregnancy. Arch Gynecol Obstet 270: 79-85.
17. Norgard B, Czeizel AE, Rockenbauer M et al. (2001) Population based case control study of the safety of sulphasalazine use.during pregnancy. Aliment Pharmacol Ther 15: 483-486.
18. Jarnerot G, Into-Malmberg MB (1979) Sulphasalazine treatment during breast feeding. Scan J Gastroenterol 14: 869-871.
19. Østensen M (2004) Disease specific problems related to drug therapy in pregnancy. Lupus 13: 746-750.
20. Hernandez-Diaz S, Werler MM, Walker AM et al. (2001) Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 153: 961-968.
21. Bar Oz B, Hackman R, Einarson T et al. (2001) Pregnancy outcome after cyclosporine therapy during pregnancy: A meta-analysis. Transplantation 71: 1051 – 1055.
22. Lamarque V, Leleu MF, Monka C et al. (1997) Analysis of 629 pregnancy outcomes in transplant recipients treated with Sandimmun. Transplant Proc 29: 2480.
23. Moskovitz DN, Bodian C, Chapman ML et al. (2004) The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 99: 656-661.
24. Meehan RT, Dorsey JK (1987) Pregnancy among patients with systemic lupus erythematosus receiving immunosuppressive therapy. J Rheumatol 14: 252 – 258.
25. Ramsey-Goldman R, Mientus JM, Kutzer JE et al. (1993) Pregnancy outcome in women with systemic lupus erythematosus treated with immunosuppressive drugs. J Rheumatol 20: 1152-1157.
26. Østensen M (2004) Disease specific problems related to drug therapy in pregnancy. Lupus 13: 746-750.
27. Briggs; G.G. et al. (2005) Drugs in pregnancy and Lactation, 7th edition; Lippincott Williams & Wilkins.
28. Zerner, J. et al. (1981) Intrauterine contraceptive device failures in renal transplant patients. J Reprod Med 26: 99-102.
29. Lloyd ME, Carr M, McElhatton P et al. (1999) The effects of methotrexate on pregnancy, fertility and lactation. O J Med 92: 551-563.
30. Østensen M, Hartmann H, Salvesen K (2000) Low dose weekly methotrexate in early pregnancy: A case series and review of the literature. J Rheumatol 27: 1872-1875.
31. Chakravarty EF, Sanchez-Yamamoto D, Bush TM (2003) The use of disease-modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: A survey of practice patterns and pregnancy outcomes. J Rheumatol 30: 241-246.
32. Johns DG, Rutherford LD, Leighton PC et al. (1972) Secretion of methotrexate into human milk. Am J Obstet Gynaecol 112: 978-980.
33. Brent RL (2001) Teratogen Update: Reproductive risks of leflunomide, a pyrimidine synthesis inhibitor. Counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 63: 106 – 112.
34. Boumpas DT, Austin HA, Vaughan EM et al. (1993) Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119: 366-369.
35. Mirkes PE (1985) Cyclophosphamide teratogenesis: A review. Teratog Carcinog Mutagen 5: 75 – 88.
36. Enns GM, Roeder E, Chan RT et al. (1999) Apparent cyclophosphamide embryopathy: A distinct phenotype? Am J Med Gen 86: 237 – 241.
37. Wiernik PH, Duncan JH (1971) Cyclophosphamide in human milk. Lancet 1971-1: 912.
38. Pergola PE, Kancharla A, Riley DJ (2001) Kidney transplantation during the first trimenon of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus and prednisone. Transplantation 71: 994-997.
39. Sifontis NM, Coscia LA, Constantinescu S, et al. (2006) Pregnancy Outcomes in Solid Organ Transplant Recipients With Exposure to Mycophenolate Mofetil or Sirolimus. Transplantation 82: 1698–1702
40. Østensen M, Khamashta M, Lockshin M et al. (2006) Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 8: 209.
41. Strangfeld A, Listing J, Rau R et al. (2007) Pregnancy outcome after exposure to biologics: Results from the German Biologics Register RABBIT. Arthritis Rheum 56, Suppl., S 311.
42. Katz JA, Antoni C, Keenan GF et al. (2004) Outcome of Pregnancy in Women Receiving Infliximab for the Treatment of Crohn´s Disease and Rheumatoid Arthritis. Am J Gastroenterol 99: 2385 – 2392.
43. Orozco C, Dao K, Cush JJ et al. (2005) Safety of TNF inhibitors during pregnancy in patients with inflammatory arthritis. ACR Annual Scientific Meeting San Diego, Abstr. F12.
44. Carter JD, Ladhani A, Ricca L et al. (2007) A safety assessment of TNF Antagonists during pregnancy: A review of the FDA database. Arthritis Rheum 56, Suppl., S 286.
45. Kallinich T, Haffner d, Niehues T et al. (2007) Colchicine use in children and adolescents with familial Mediterranean fever: Literature review and consensus statement. Pediatrics 119: e474-e483.
46. Berkenstad M, Weisz B, Cuckle H et al. (2005) Chromosomal abnomalities and birth defects among couples with colchicine treated familial Mediterranean fever. Am J Obstet Gynecol 193: 1513-1516.
47. Ben-Chetrit E, Levy M (2003) Reproductive system in familial Mediterranean fever: an overview. Ann Rheum Dis 62: 916-919.
48. Rabinovitch O, Zemer D, Kukia E et al. (1992) Colchicine treatment in conception and pregnancy: 231 pregnancies in patients with familial Mediterranean fever.
49. Ben-Chetrit E, Berkun Y, Ben_Chetrit E et al. (2004) The outcome of pregnancy in the wives of men with familial Mediterranian fever. Semin Arthritis Rheum 34: 549-552.
50. Committee on Drugs, American Academy of Pediatrics (1994) The transfer of drugs and other chemicals into human milk. Pediatrics 93: 137-150.
51. Radder CM, Roelen DL, van de Meer-Prins et al. (2004) The immunologic profile of infants born after maternal immunoglobulin treatment and intrauterine platelet transfusions for fetal/neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 191: 815-820
52. Schaefer C, Hannemann D, Keister R et al. (2006) Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Throm Haemost 95: 949-957.
53. Segal JB, Streiff MB, Hofmann LV et al. (2007) Management of Venous Thromboembolism: A Systematic Review for a Practice Guideline. Ann Intern Med 146: 211-222
54. Bates SM, Greer IA, Pabinger I et al. (2008) Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 844-886
55. Chan WS, Anand S, Ginsberg JS (2000) Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med: 160:191-6
56. James AH, Grotegut CA, Brancazio LR et al. (2007) Thromboembolism in Pregnancy: Recurrence and Its Prevention. Semin Perinatol 31: 167-175